Clobetasone
Classification: BATC code: D07AB01
Summary
Published controlled studies on differences between men and women regarding efficacy and safety of clobetasone are lacking.
Additional information
Pharmacokinetics and dosing
Topical corticosteroids may be systematically absorbed if used on large areas, on broken skin, or under occlusive dressings [2]. No difference between men and women has been shown for transdermal absorption in general [3].
Effects
No studies with a clinically relevant sex-analysis regarding the effects of clobetasone have been found.
Adverse effects
No studies with a clinically relevant sex-analysis regarding adverse effects of clobetasone have been found.
Reproductive health issues
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Other information
A retrospective analysis of patients with eczema or psoriasis on standard dermatological treatment (295 men, 291 women) found that significantly more men than women (79; 63%, 47; 37%) were administered whole-body UV treatment. Also, the results indicated that men had more treatments appointments per individual than women. Women were prescribed more emollients than men [1].
Updated: 2020-08-28
Date of litterature search: 2017-02-02
References
- Nyberg F, Osika I, Evengård B. "The Laundry Bag Project"--unequal distribution of dermatological healthcare resources for male and female psoriatic patients in Sweden. Int J Dermatol. 2008;47:144-9. PubMed
- Martindale: The Complete Drug Reference. Pharmaceutical Press.
- Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107-21. PubMed
- Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2017-01-26.] länk
Reviewed by: Mia von Euler
Approved by: Linnéa Karlsson Lind